Plafibride tolerance trial in healthy volunteers

Area of Science:

• Pharmacology
• Clinical Medicine
• Cardiovascular Research

Background:

• Platelet aggregation and lipid metabolism are key factors in cardiovascular health.
• Acetylsalicylic acid (ASA) is a widely used antiplatelet agent with known gastrointestinal side effects.
• Novel therapeutic agents with improved safety profiles are needed for cardiovascular disease management.

Purpose of the Study:

• To evaluate the tolerance and efficacy of plafibride (ITA 104) in healthy volunteers over a 3-month period.
• To compare the antiplatelet and hypolipemic effects of plafibride with acetylsalicylic acid (ASA).
• To assess the clinical and analytical safety of plafibride.

Main Methods:

• A 3-month, open-label study in healthy volunteers.
• Oral administration of plafibride or ASA at 1600 mg/d.
• Assessment of platelet antiaggregant activity, gastrointestinal tolerance, and lipid profiles (total lipids, triglycerides, lipoproteins).

Main Results:

• Plafibride exhibited a platelet antiaggregant effect comparable in intensity to ASA.
• Plafibride demonstrated significantly better gastrointestinal tolerance than ASA.
• Plafibride induced a hypolipemic effect, decreasing total lipids and triglycerides, and altering lipoprotein fractions without rebound.
• Overall clinical and analytical tolerance of plafibride was very good.

Conclusions:

• Plafibride is a well-tolerated drug with comparable antiplatelet efficacy to ASA.
• Plafibride possesses beneficial hypolipemic properties.
• Plafibride represents a promising therapeutic option with an improved safety profile for managing cardiovascular risk factors.